Colorectal Cancer | Specialty

Contribution of HIPEC to Cytoreductive Surgery in CRC Peritoneal Carcinomatosis Warrants Further Investigation

January 13th 2021

Prakash Pandalai, MD, highlighted the survival benefit of cytoreductive surgery in colorectal cancer peritoneal carcinomatosis and how it has been well documented.

Aggressive Treatment Approaches May Move Dial in Metastatic Colon Cancer

January 13th 2021

Michael J. Cavnar, MD, highlights the role of surgery in colon cancer, the role of tumor sidedness in informing surgical decisions, and research efforts that are being done to evaluate the utility of hepatic artery infusion pumps.

Dr. Chalabi on the Role of MSI Testing in CRC

January 13th 2021

Myriam Chalabi, MD, discusses the utility of microsatellite instability (MSI) testing in colorectal cancer,

Adjuvant Oxaliplatin Added to Fluoropyridine Improves Survival in Stage III MSI-High Colon Cancer

January 12th 2021

The addition of adjuvant oxaliplatin to fluoropyridine improves overall survival and disease-free survival compared with fluoropyridine alone in patients with stage III colon cancer with microsatellite instability.

Dr. Chalabi on the Importance of Testing for MSI and dMMR in CRC

January 12th 2021

Myriam Chalabi, MD, highlights the importance of testing for microsatellite instability and mismatch repair deficiency in colorectal cancer.

Dr. Mai on Guidelines for Genetic Testing in CRC

January 8th 2021

Phuong L. Mai, MD, discusses guidelines for genetic testing in colorectal cancer.

Vemurafenib Plus Cetuximab/Irinotecan Improves PFS in BRAF-Mutant Metastatic CRC

January 6th 2021

January 6th, 2021 - The addition of vemurafenib to irinotecan and cetuximab led to a significant improvement in progression-free survival versus irinotecan and cetuximab alone in patients with BRAF V600E–mutated metastatic colorectal cancer.

Dr. Grothey on the Results of the ANCHOR-CRC Trial in BRAF V600E-Mutant mCRC

January 4th 2021

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.

Pinpointing the Need for Genetic Testing in Oncology

December 31st 2020

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

Oncolytics Biotech Launches Trial of Pelareorep/Atezolizumab Combo in Difficult-to-Treat GI Cancers

December 30th 2020

December 30, 2020 - The phase 1/2 GOBLET trial will investigate the use of pelareorep in combination with atezolizumab in patients with metastatic colorectal and advanced or metastatic pancreatic and anal cancers.

x